Combination checkpoint therapy with anti-PD-1 and anti-BTLA results in a synergistic therapeutic effect against murine glioblastoma-Reference-Cited by-同舟云学术

Combination checkpoint therapy with anti-PD-1 and anti-BTLA results in a synergistic therapeutic effect against murine glioblastoma

Published:2021-01-01 Issue:1 Volume:10 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Choi John¹,Medikonda Ravi¹,Saleh Laura¹,Kim Timothy¹,Pant Ayush¹,Srivastava Siddhartha¹,Kim Young-Hoon²,Jackson Christina¹,Tong Luqing¹,Routkevitch Denis¹,Jackson Christopher¹,Mathios Dimitrios¹^ORCID,Zhao Tianna¹,Cho Hyerim³,Brem Henry¹,Lim Michael¹^ORCID

Affiliation:

1. Department of Neurosurgery, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, USA

2. Department of Neurosurgery, College of Medicine, Asan Medical Center, University of Ulsan, Seoul, Republic of Korea

3. Department of Radiology, Seoul National University College of Medicine, Seoul, Republic of Korea

Funder

Funding from Arbor Pharmaceuticals

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2021.1956142

Reference36 articles.

1. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014

2. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma

3. Di Carlo DT, Cagnazzo F, Benedetto N, Morganti R, Perrini P. Multiple high-grade gliomas: epidemiology, management, and outcome. A systematic review and meta-analysis. Vol. 42, Neurosurgical Review. Springer Verlag; 2019. p. 263–275.

4. Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

5. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy;Journal of Translational Medicine;2024-08-09

2. The Immune Checkpoint BTLA in Oral Cancer: Expression Analysis and Its Correlation to Other Immune Modulators;International Journal of Molecular Sciences;2024-06-15

3. Targeting BTLA with the peptide inhibitor HVEM(14-39) – A new way to restore the activity of T cells in melanoma;Biomedicine & Pharmacotherapy;2024-06

4. The BTLA–HVEM axis restricts CAR T cell efficacy in cancer;Nature Immunology;2024-06

5. The BTLA-HVEM complex – The future of cancer immunotherapy;European Journal of Medicinal Chemistry;2024-03